Compare TTI & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTI | TNDM |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1996 | 2013 |
| Metric | TTI | TNDM |
|---|---|---|
| Price | $5.98 | $19.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 25 |
| Target Price | $11.13 | ★ $27.76 |
| AVG Volume (30 Days) | ★ 2.5M | 1.8M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $4.30 | $5.69 |
| Revenue Next Year | $8.89 | $12.35 |
| P/E Ratio | $46.46 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $4.87 | $12.26 |
| 52 Week High | $12.54 | $29.65 |
| Indicator | TTI | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 67.74 |
| Support Level | $5.64 | $17.61 |
| Resistance Level | $6.31 | $20.79 |
| Average True Range (ATR) | 0.28 | 0.93 |
| MACD | 0.10 | 0.49 |
| Stochastic Oscillator | 85.55 | 84.70 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.